Literature DB >> 22391030

Glutamate-based depression GBD.

Dennis J McCarthy1, Robert Alexander, Mark A Smith, Sanjeev Pathak, Stephen Kanes, Chi-Ming Lee, Gerard Sanacora.   

Abstract

We describe a new term: glutamate-based depression (GBD). GBD is defined as a chronic depressive illness associated with environmental stress and diseases associated with altered glutamate neurotransmission. We hypothesize that glutamate-induced over-activation of extrasynaptic NMDA receptors in the subgenual cingulate area called Brodmann's 25 plays an important role in the etiology of depression and may be responsible for the high incidence of co-morbid depression associated in diseases with glutamate etiology. While depression is a syndrome with multiple possible etiologies, we propose that a disruption in glutamatergic neurotransmission may underline a substantial proportion of clinically observed depression. The high rates of depressive symptoms associated with various disorders in which altered glutamatergic functions have been identified, may suggest a common pathophysiological mechanism is underlying the diverse clinical presentations.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22391030     DOI: 10.1016/j.mehy.2012.02.009

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  16 in total

1.  Modulation of DNA Methylation and Gene Expression in Rodent Cortical Neuroplasticity Pathways Exerts Rapid Antidepressant-Like Effects.

Authors:  Amanda J Sales; Izaque S Maciel; Angélica C D R Suavinha; Sâmia R L Joca
Journal:  Mol Neurobiol       Date:  2020-10-06       Impact factor: 5.590

Review 2.  Pharmacological management of depression in patients with cancer: practical considerations.

Authors:  Riccardo G V Torta; Valentina Ieraci
Journal:  Drugs       Date:  2013-07       Impact factor: 9.546

Review 3.  Ameliorating treatment-refractory depression with intranasal ketamine: potential NMDA receptor actions in the pain circuitry representing mental anguish.

Authors:  Lewis A Opler; Mark G A Opler; Amy F T Arnsten
Journal:  CNS Spectr       Date:  2015-01-26       Impact factor: 3.790

4.  Stereoselective Synthesis of New (2S,3R)-3-Carboxyphenyl)pyrrolidine-2-carboxylic Acid Analogues Utilizing a C(sp3)-H Activation Strategy and Structure-Activity Relationship Studies at the Ionotropic Glutamate Receptors.

Authors:  Silke Kayser; Jacob C Hansen; Markus Staudt; Aleksandra Moroz; Younes Larsen; Piero Temperini; Feng Yi; Jed T Syrenne; Niels Krogsgaard-Larsen; Stylianos Iliadis; Birgitte Nielsen; Kasper B Hansen; Darryl S Pickering; Lennart Bunch
Journal:  ACS Chem Neurosci       Date:  2020-02-17       Impact factor: 4.418

Review 5.  Therapeutic potential of targeting glutamate receptors in Parkinson's disease.

Authors:  Clare Finlay; Susan Duty
Journal:  J Neural Transm (Vienna)       Date:  2014-02-21       Impact factor: 3.575

Review 6.  Second messenger/signal transduction pathways in major mood disorders: moving from membrane to mechanism of action, part I: major depressive disorder.

Authors:  Mark J Niciu; Dawn F Ionescu; Daniel C Mathews; Erica M Richards; Carlos A Zarate
Journal:  CNS Spectr       Date:  2013-03-05       Impact factor: 3.790

Review 7.  Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction.

Authors:  Alan L Pehrson; Connie Sanchez
Journal:  CNS Spectr       Date:  2013-08-01       Impact factor: 3.790

Review 8.  Recent Advance in the Relationship between Excitatory Amino Acid Transporters and Parkinson's Disease.

Authors:  Yunlong Zhang; Feng Tan; Pingyi Xu; Shaogang Qu
Journal:  Neural Plast       Date:  2016-02-14       Impact factor: 3.599

Review 9.  The neurobiological pathogenesis of poststroke depression.

Authors:  Chao Feng; Min Fang; Xue-Yuan Liu
Journal:  ScientificWorldJournal       Date:  2014-03-04

Review 10.  Potential and Challenges for the Clinical Use of d-Serine As a Cognitive Enhancer.

Authors:  Gerson D Guercio; Rogerio Panizzutti
Journal:  Front Psychiatry       Date:  2018-02-05       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.